2025-10-19 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX) based on the information you provided, presented in a structured format suitable for a report.

## Recursion Pharmaceuticals Inc. (RXRX) Analysis

**Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging AI and machine learning to discover and develop novel therapeutics.

---

### 1. Performance Relative to S&P 500 (VOO)

*   **Cumulative Return RXRX:** -6.45%
*   **Cumulative Return VOO:** 39.04%
*   **Absolute Divergence:** -44.49%
*   **Divergence Range:** Max: 84.1, Min: -64.3
*   **Relative Divergence:** 13.4 (Indicates RXRX's performance is near the lower end of its historical divergence range compared to VOO).

This indicates significant underperformance compared to the S&P 500 over the analyzed period.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD  | Alpha  | Beta  | Cap(B) |
| ---------- | ------- | ----- | ------ | ----- | ------ |
| 2021-2023 | 22.0%   | 81.0% | 26.0%  | -0.2  | 4.3    |
| 2022-2024 | 11.0%   | 81.0% | -10.0% | 0.1   | 3.0    |
| 2023-2025 | 36.0%   | 80.0% | -26.0% | 0.1   | 2.6    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) varies significantly across the periods.
*   **MDD:** High Maximum Drawdown (MDD) values consistently around 80% indicate very high volatility and risk.
*   **Alpha:** Alpha values fluctuate significantly, indicating inconsistent outperformance or underperformance relative to the market.
*   **Beta:** Beta values are close to zero, suggesting RXRX's price movements are not strongly correlated with the overall market (S&P 500).
*   **Cap:** The company's market capitalization has decreased over the observed periods, from $4.3B to $2.6B.

### 2. Recent Stock Price Fluctuations

*   **Current Price:** 5.86
*   **Previous Close:** 6.36
*   **Change:** -7.86% (Significant Drop)
*   **5-Day Moving Average:** 6.086
*   **20-Day Moving Average:** 5.3993
*   **60-Day Moving Average:** 5.2475

The stock price has experienced a notable drop in the most recent trading session. The current price is below the 5-day moving average but above the 20-day and 60-day moving averages, suggesting potential short-term downward momentum but still above longer-term trends.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment Recommendation)
*   **RSI:** 60.12 (Approaching Overbought)
*   **PPO:** 1.72 (Positive Momentum)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (195 shares - Very Safe - MRI:0.90) Monthly invest 1.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Divergence Change:** +8.5 (Short-term Increase in Relative Performance)
*   **Expected Return:** -28.0% (Long-Term Underperformance vs. S&P 500)

The MRI suggests a low investment recommendation due to the risk involved. RSI indicates the stock is approaching overbought territory. The PPO indicates positive momentum. Despite recent positive divergence, the long-term expected return is negative. The recent price drop (-7.86%) confirms the volatility and risk associated with the stock.

### 4. Recent News & Significant Events

*   **Positive Headlines:**  Several articles highlight Recursion's AI strategy and potential for growth.
*   **Negative Headlines:** One article indicates Recursion underperformed the general market.

**Key Observations:** The news flow presents a mixed picture, with some articles focusing on growth potential and AI capabilities, while others highlight underperformance. The market seems to be reacting to Recursion's AI event.

### 4-2. Analyst Opinions

*   **Consensus:** Hold (Mean: 2.62)
*   **Target Price:** Avg: 6.47 / High: 10.00 / Low: 3.00

Analysts, on average, have a "Hold" recommendation.  The average target price suggests potential upside, but the wide range (3.00 to 10.00) indicates significant uncertainty. There is no information about recent rating changes.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출        |
| ---------- | ----- | ----------- |
| 2025-08-05 | -0.41 | 0.02 B$     |
| 2025-05-05 | -0.5  | 0.01 B$     |
| 2024-11-06 | -0.34 | 0.03 B$     |
| 2024-08-08 | -0.4  | 0.01 B$     |
| 2025-08-05 | -0.4  | 0.01 B$     |

**Analysis:** Recursion has consistently reported negative EPS, indicating losses. Revenue has been variable but generally low, in the range of $0.01B to $0.03B per quarter.

### 6. Financial Information

| Quarter    | Revenue    | Profit Margin |
| ---------- | ---------- | ------------- |
| 2025-06-30 | \$0.02B    | -5.54%        |
| 2025-03-31 | \$0.01B    | -47.31%       |
| 2024-12-31 | \$0.00B    | -183.62%      |
| 2024-09-30 | \$0.03B    | 53.69%        |
| 2024-06-30 | \$0.01B    | 36.14%        |

| Quarter    | Equity     | ROE       |
| ---------- | ---------- | --------- |
| 2025-06-30 | \$0.92B    | -18.70%   |
| 2025-03-31 | \$0.93B    | -21.68%   |
| 2024-12-31 | \$1.03B    | -17.29%   |
| 2024-09-30 | \$0.52B    | -18.27%   |
| 2024-06-30 | \$0.58B    | -16.69%   |

**Analysis:**

*   **Revenue:** Revenue is inconsistent across quarters.
*   **Profit Margin:** Profit margins are generally negative, with a few quarters showing positive margins. The negative margins are quite significant in some quarters.
*   **Equity:** Equity has fluctuated.
*   **ROE:**  Return on Equity (ROE) is consistently negative, reflecting the company's inability to generate profits from its equity.

### 7. Overall Assessment

RXRX presents a high-risk, high-potential reward profile. The company is underperforming the S&P 500 significantly, has high volatility (high MDD), and is currently operating at a loss.  However, the focus on AI and some positive news headlines suggest potential for future growth. Analyst opinions are neutral, and the target price range is wide. The recent stock price drop underscores the inherent risks. Investing in RXRX requires careful consideration of the company's long-term prospects and risk tolerance.
